Relapsed or Refractory Multiple Myeloma Video Perspectives

In this video, Sagar Lonial, MD, FACP, professor of hematology and oncology at Emory University School of Medicine, discusses:

• combination therapy “ruling the day” in refractory, relapsed myeloma;
• ways passive immunity and antibodies dramatically altered depth and durability of response and goals in terms of remission and cure;
• why long-term trails on the progression-free survival curve in CAR T-cells are “disappointing”;
• considering seventh generation CARs to improve persistence and reduce incidence of CRS or other toxicities;
• exciting new target bispecific targets in multiple myeloma, GPRC5D and anti-FCRH5; and
• unmet needs in developing new targets and improving remission rates in CAR T-cell therapy.